Zacks Investment Research
02 Jul 2026, 15:51 UTC · 3h ago
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
02 Jul 2026, 15:51 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Tango Therapeutics' vopimetostat-daraxonrasib combination showed a 92% objective response rate and 90% six-month progression-free survival rate in 12 evaluable patients with MTAP-deleted, RAS-mutant pancreatic cancer. — High clinical efficacy in a difficult-to-treat cancer typically triggers significant positive sentiment and valuation increases for clinical-stage biotech.
+0.80Tango Therapeutics has ceased receiving collaboration revenue from Gilead, with Q1 2026 revenue dropping to zero from $5.4 million a year prior. — The loss of a major partner's funding increases the company's cash burn risk and dependence on future financing or successful clinical readouts.
-0.50Tango Therapeutics expects multiple 2026 readouts, including vopimetostat monotherapy data in lung cancer and initial TNG456 data in glioblastoma. — Upcoming catalysts create potential for further upside but increase stock volatility based on the results.
+0.40Continue reading
6 related stories
Top 1 mover · tap to explore
The company remains a clinical-stage entity with no approved products, no recurring product revenues, and a valuation that already discounts meaningful success. — Signals that much of the positive news may already be 'priced in,' limiting further upside unless results exceed high expectations.
-0.30Which stocks this story touches
Strong clinical data and significant share price rally, though tempered by a lack of revenue and high valuation.
Mentioned as a partner providing a key inhibitor for positive combination therapy results.
Mentioned as a potential combination partner for future clinical evaluation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
3h ago
